COMMUNITY CLINICAL ONCOLOGY PROGRAM

北中原癌症治疗车中的梅奥诊所 集团(NCCTG)将作为以下主要研究基地 CCOP‘s：Alton Ochsner医学基金会，Carle癌症中心，雪松 急流肿瘤学项目，德卢斯诊所，盖辛格诊所和医疗 伊利诺伊州肿瘤研究协会爱荷华州肿瘤研究中心， 拉皮特市区域肿瘤协会，圣卢克医院， 苏族社区癌症联盟和托莱多。我们还将作为 非CCOP肿瘤控制协议活性的研究基础 参与者和我们组外的多名CCOP 为小组间癌症治疗和癌症控制方案做出贡献 由我们来领导。我们将与我们所属的CCOP合作规划 他们的计划，并进行适当的继续教育和 研讨会。我们将为他们的数据提供培训和积极的支持 经理和肿瘤科护士。我们将协调他们的多学科 参与临床癌症研究方案。这将包括 发展和维护外科手术的标准报告程序， 病理学和放射治疗。我们将定期举行会议。 CCOP用于审查正在进行的研究，规划未来的研究，以及 与之相关的专业活动。我们将延续僵化的品质 过去被证明非常成功的控制程序，以及 如图所示升级这些程序。我们将持续监控CCOP 不仅通过及时审查患者的数据表、病理来表现 材料、手术报告和放射治疗端口胶片，而且 通过定期随机安排的监测现场访问。我们将与 每个CCOP参与者作为临床参与者帮助他们成熟 调查人员。我们将帮助他们制定新的协议， 他们将分享领导力，我们将与他们合作准备 出版物以及为国家和区域会议所作的介绍。 我们将尽一切努力让他们有理由为他们的 参与国家癌症计划。比这更优先的事情 授权期将扩大我们对癌症的控制努力 通过纳入相关的基本实验室支持进行预防。

The Mayo Clinic through the vehicle of the North Central Cancer Treatment Group (NCCTG) will serve as primary research base for the following CCOP's: Alton Ochsner Medical Foundation, Carle Cancer Center, Cedar Rapids Oncology Project, the Duluth Clinic, Geisinger Clinic nd Medical Center, Illinois Oncology Research Association, Iowa Oncology Research, Association Rapid City Regional Oncology Group, St. Luke's Hospitals, Sioux Community Cancer Consortium, and Toledo. We will also serve as research base for cancer control protocol activity of non-CCOP participants and for the multiple CCOP's outside of our group who contribute to intergroup cancer treatment and cancer control protocols which we lead. We will cooperate with our affiliated CCOP's in planning their program and in conducting appropriate continuing education and workshops. We will provide training and active support for their data managers and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. This will include evolving and maintaining standard reporting procedures for surgery, pathology, and radiation therapy. We will hold regular meetings of the CCOP's for review of ongoing research, planning future research, and for related professional activities. We will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP performance not only by timely review of patient data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic randomly scheduled monitoring site visits. We will work with each CCOP participant to aid in their maturation as clinical investigators. We will assist them in developing new protocols for which they will share leadership and we will work with them in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide them with justifiable pride in their participation in the National Cancer Program. A high priority over this grant period will be expansion of our control efforts into cancer prevention with incorporation of associated basic laboratory support.